Pharma Hemp ®
LABORATORIES

ilac-MRA

SLOVENSKA AKREDITACIJA
SIST EN ISO/IEC 17025
LP-117

CERTIFICATE OF ANALYSIS No.: 2021-6717

CLIENT

SPECTRUMLEAF CANNADIPS SPÓŁKA Z OGRANICZONĄ
ODPOWIEDZIALNOŚCIĄ, 27 Grudnia 3
61-737 Poznan, Poland

SAMPLE

Cannadips Natural Mint

Sample condition:	SUITABLE	Work order:	2021-105822	Sample received:	05/11/2021
Sample ID:	2144055	Analysis ID:	2021_258	Start of analysis:	08/11/2021
Sample type:	Powder	Method ID:	PHL_RPC_12C	End of analysis:	09/11/2021
Batch No.:	101219	Method SOP:	MET-002-03	Analyst:	Karmen Korbar

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	LOQ [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	0.0089	0.0020	0.00300	
CBDA	- Cannabidiolic acid	< LOQ	n/a	0.00300	
CBGA	- Cannabigerolic acid	< LOQ	n/a	0.00300	
CBG	- Cannabigerol	0.0105	0.0031	0.00300	
CBD	- Cannabidiol	1.661	0.083	0.00300	
THCV	- Tetrahydrocannabivarin	< LOQ	n/a	0.00300	
CBN	- Cannabinol	0.0170	0.0037	0.00300	
CBC	- Cannabichromene	0.0256	0.0056	0.00300	
THC	- Δ-9-Tetrahydrocannabinol	< LOQ	n/a	0.00300	
THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	0.00300	
8-THC	- Δ-8-Tetrahydrocannabinol *	< LOQ	n/a	0.00300	
CBL	- Cannabicyclol *	< LOQ	n/a	0.00300	

The results marked by * relate to non-accredited activity.

Units and abbreviations: **% w/w** = weight percent, **LOQ** = the limit of quantitation, **ND** = not detected, **n/a** = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

09/11/2021

Approved by:

mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate